All News
Comorbidities Increase in Importance in RA
Patients with rheumatoid arthritis (RA) have a large comorbidity burden at the time of diagnosis, including a wide range of ailments but with pulmonary disease a particular concern, a U.K. population-based study found.
Read Article
Comorbidity Worsens Axial Spondyloarthritis
Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.
Read Article
Warfarin Superior to Xarelto in Antiphospholipid Syndrome
A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.
Read Article
Juvenile Arthritis at Risk for Coronary Artery Disease
Arthritis Care & Research reports that juvenile arthritis (JA) patients may have a higher risk if coronary artery disease (CAD) in adulthood.
Read Article
ILD Patients At Risk for Autoimmune Disease
Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).
Read Article
RheumNow Podcast – Women Take Over Rheumatology (10.4.19)
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
Read Article
RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Read Article
Higher Rates of Venous Thromboembolism in Gout
A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.
Read Article
RheumNow Podcast – Believe in Vitamin D or Rituximab? (9.20.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
NSAID Use Linked With Hypertension in Ankylosing Spondylitis
Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.
Read Article
RheumNow Podcast – The End of Arthritis (9.13.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Nintedanib FDA Approved for Scleroderma Lung Disease
Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.
ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.
Respiratory Risks Not Increased in RA Patients with COPD
An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs.
A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).
Tocilizumab Shows No Increase in Cardiovascular Risk
The ENTRACTE trial examined the risk for major adverse cardiovascular events (MACE) in RA patients and found no increased risk of MACE in patients treated with tocilizumab (TCZ) versus etanercept (ETN).
Read Article
High-Dose Vitamin D: No Help for Bone Health
Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances.
In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven Boyd, PhD, of the University of Calgary in Canada, and colleagues.
Osteoporosis Tx: Good for Bones, but Not for Cutting Death Risk
Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data.
Read Article
RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)
Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.
Read Article
Bisphosphonate Use Associated with Reduced Mortality
The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.
Read Article
RA Disease Activity Drives Lung Complications
A longitudinal study from the BRASS registry shows that increase rheumatoid arthritis disease activity increases the risk of RA-associated interstitial lung disease (RA-ILD).
RA patients without RA-ILD at baseline, enrolled in the Brigham RA Sequential Study (BRASS, 2003–2016), were followed from 2003-2016 with serial clinical, DAS28, serologic and imaging assessments.
NSAIDs Mediate Cardiovascular Risk in OA
NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.
Read Article
